A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
Phase of Trial: Phase I
Latest Information Update: 11 May 2018
At a glance
- Drugs SVN53-67-M57-KLH peptide vaccine (Primary) ; Lenalidomide; Sargramostim
- Indications Multiple myeloma
- Focus Adverse reactions
- 03 May 2018 Planned End Date changed from 9 Nov 2019 to 9 Nov 2023.
- 03 May 2018 Planned primary completion date changed from 9 Nov 2018 to 9 Nov 2022.
- 10 Jun 2017 Biomarkers information updated